CIPM: molecules with a published decision record

274 molecules on this site carry at least one CIPM decision. Each page compares that decision with every other agency that assessed the same molecule.

MoleculeDecisionsAgenciesClass
pembrolizumab37115Antineoplastics
nivolumab26415Antineoplastics
atezolizumab12014Antineoplastics
dupilumab11615Other dermatologicals
daratumumab11515Antineoplastics
olaparib11415Antineoplastics
durvalumab10815Antineoplastics
ibrutinib10815Antineoplastics
paracetamol1064Analgesics
upadacitinib9316Immunosuppressants
ivacaftor7912Other respiratory
secukinumab7912Immunosuppressants
budesonide7612Antidiarrheals / intestinal anti-inflammatories
ustekinumab7111Immunosuppressants
infliximab699Immunosuppressants
lenalidomide6813Immunosuppressants
aflibercept6711Antineoplastics
denosumab6711Bone diseases
osimertinib6514Antineoplastics
blinatumomab6414Antineoplastics
dapagliflozin6412Diabetes
empagliflozin6413Diabetes
trastuzumab deruxtecan6414Antineoplastics
venetoclax6114Antineoplastics
tofacitinib6013Immunosuppressants
mepolizumab5915Obstructive airway diseases
glucose587Blood substitutes and perfusion
ipilimumab5814Antineoplastics
zanubrutinib5816Antineoplastics
trastuzumab579Antineoplastics
cabozantinib5615Antineoplastics
guselkumab5613Immunosuppressants
risankizumab5614Immunosuppressants
bimekizumab5514Immunosuppressants
cemiplimab5513Antineoplastics
rivaroxaban5511Antithrombotics
brentuximab vedotin5412Antineoplastics
ravulizumab5415Immunosuppressants
selpercatinib5313Antineoplastics
semaglutide5314Diabetes
acalabrutinib5214Antineoplastics
enzalutamide5212Endocrine therapy
ribociclib5014Antineoplastics
ruxolitinib5012Antineoplastics
lenvatinib4914Antineoplastics
nintedanib4915Antineoplastics
baricitinib4814Immunosuppressants
tislelizumab4812Antineoplastics
amivantamab4713Antineoplastics
vedolizumab4412Immunosuppressants
golimumab4310Immunosuppressants
omalizumab4312Obstructive airway diseases
avelumab4213Antineoplastics
niraparib4215Antineoplastics
aripiprazole418Psycholeptics
dostarlimab3914Antineoplastics
eculizumab3911Immunosuppressants
dabrafenib3814Antineoplastics
darolutamide3815Endocrine therapy
isatuximab3812Antineoplastics
alectinib3715Antineoplastics
alirocumab3713Lipid modifying agents
obinutuzumab3712Antineoplastics
tisagenlecleucel3712Antineoplastics
buprenorphine367Other nervous system
crizotinib3512Antineoplastics
emicizumab3512Antihemorrhagics
melatonin358Psycholeptics
abatacept3410Immunosuppressants
axicabtagene ciloleucel3412Antineoplastics
burosumab3413Bone diseases
dexamethasone348Ophthalmologicals
esketamine3313Psychoanaleptics
natalizumab3312Immunosuppressants
pegcetacoplan3316Ophthalmologicals
carfilzomib3211Antineoplastics
hydrocortisone3210Systemic corticosteroids
pertuzumab3213Antineoplastics
benralizumab3115Obstructive airway diseases
fluticasone318Nasal preparations
ramucirumab319Antineoplastics
sacituzumab govitecan3115Antineoplastics
avapritinib3011Antineoplastics
entrectinib3013Antineoplastics
midazolam309Psycholeptics
regorafenib3012Antineoplastics
larotrectinib2914Antineoplastics
sofosbuvir2911Antivirals
apremilast2810Immunosuppressants
belimumab2812Immunosuppressants
encorafenib2812Antineoplastics
letermovir2814Antivirals
tafamidis2816Other nervous system
enfortumab vedotin2713Antineoplastics
lisocabtagene maraleucel2711Antineoplastics
pemetrexed276Antineoplastics
vutrisiran2715Other nervous system
fenfluramine2614Antiepileptics
filgotinib2613Immunosuppressants
glofitamab2613Antineoplastics

How these pages are produced · HTA Outcomes